Prezcobix Dosage

Generic name: DARUNAVIR ETHANOLATE 800mg, COBICISTAT 150mg
Dosage form: tablet, film coated
Drug class: Antiviral combinations

Medically reviewed by Drugs.com. Last updated on Apr 2, 2025.

Recommended Dosage in Adults and Pediatric Patients Weighing at Least 25 kg

The recommended dosages of PREZCOBIX for adults and pediatric patients weighing at least 25 kg are shown in Table 1. The pediatric dose is based on weight. Administer PREZCOBIX orally with food in conjunction with other antiretroviral agents.

Table 1: Recommended Dosages of PREZCOBIX in Adults and Pediatric Patients Weighing at Least 25 kg, who are Treatment-Naïve or Treatment-Experienced Without DRV RAMs *
Patient Population	Dose (once daily with food)
* DRV-resistance-associated mutations (RAMs): V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V.
Adult Patients	One 800 mg darunavir/150 mg cobicistat tablet
Pediatric Patients weighing at least 40 kg	One 800 mg darunavir/150 mg cobicistat tablet
Pediatric Patients weighing at least 25 kg to less than 40 kg	One 675 mg darunavir/150 mg cobicistat tablet

Before prescribing PREZCOBIX 675 mg/150 mg tablets, children should be assessed for the ability to swallow tablets. For patients unable to swallow the 675 mg/150 mg tablet whole, the scored tablet may be split by hand into two pieces. Each piece should be consumed immediately after splitting to ensure the entire dose is administered. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Testing Prior to Initiation of PREZCOBIX

HIV Genotypic Testing

HIV genotypic testing is recommended for antiretroviral treatment-experienced patients. However, when HIV genotypic testing is not feasible, PREZCOBIX can be used in protease inhibitor-naïve patients, but is not recommended in protease inhibitor-experienced patients.

Creatinine Clearance

Prior to starting PREZCOBIX, assess estimated creatinine clearance because cobicistat decreases estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function . When co-administering PREZCOBIX with tenofovir disoproxil fumarate (tenofovir DF) assess estimated creatinine clearance, urine glucose, and urine protein at baseline .

Not Recommended in Severe Renal Impairment

PREZCOBIX co-administered with tenofovir DF is not recommended in patients who have an estimated creatinine clearance below 70 mL per minute .

Not Recommended in Severe Hepatic Impairment

PREZCOBIX is not recommended for use in patients with severe hepatic impairment .

Not Recommended During Pregnancy

PREZCOBIX is not recommended during pregnancy because of substantially lower exposures of darunavir and cobicistat during the second and third trimesters .

PREZCOBIX should not be initiated in pregnant individuals. An alternative regimen is recommended for those who become pregnant during therapy with PREZCOBIX.